Ataibeckley Inc. (ATAI) Stock Price & Analysis

Ataibeckley Inc. (ATAI) rose 0.14% to USD 7.18 as of July 25, 2026 at 15:02 UTC, according to Nexqual real-time market data.

ATAI last closed at USD 7.17; the session ranged USD 7.16–7.19 on volume of 6,894,852 shares. Market capitalization is $2.66B, with a 52-week range of USD 3.06–7.22 (NGM). Source: Nexqual, July 25, 2026 at 15:02 UTC.

Key Statistics (as of July 25, 2026 at 15:02 UTC)

Technical Analysis (ATAI)

Nexqual's technical model rates ATAI "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 15:02 UTC.

Analyst Ratings (ATAI)

Wall Street analysts rate ATAI "Hold" based on 8 analysts, with a mean price target of USD 9.59 (range USD 7.45–16), per Nexqual as of July 25, 2026 at 15:02 UTC.

Earnings (ATAI)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 15:02 UTC.

Financials & Fundamentals (ATAI)

Source: Nexqual, July 25, 2026 at 15:02 UTC.

Financial Health Score (ATAI)

Nexqual rates Ataibeckley Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 15:02 UTC.

Ownership (ATAI)

Source: Nexqual, July 25, 2026 at 15:02 UTC.

Leadership (ATAI)

Ataibeckley Inc. is led by Srinivas G. Rao (age 56), Co-Founder, CEO & Executive Director, per Nexqual as of July 25, 2026 at 15:02 UTC.

Major Backers & Investors (ATAI)

Notable institutional backers of Ataibeckley Inc. include Deep Track Capital, Lp, UBS Group AG, Adage Capital Partners GP L.L.C., according to Nexqual as of July 25, 2026 at 15:02 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 15:02 UTC.

From Ataibeckley Inc.'s Latest SEC 10-K Filing (filed 2026-03-06)

Key Strengths & Strategy (as disclosed to the SEC)

• In addition, there have been recent developments in the treatment of MDD, including AUVELITY (dextromethorphan/bupropion), a therapeutic marketed by Axsome Therapeutics, which was approved by the FDA in August 2022 and CAPLYTA (lumateperone, a therapeutic originally developed by Intra-Cellular Therapies (now Johnson & Johnson) and approved by the FDA in November 2025.
• We seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors, and non-competition, non-solicitation, confidentiality, and invention assignment agreements with our employees, consultants, and independent contractors.
• The confidentiality agreements we enter into are designed to protect our proprietary information, and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty.
• We have built a diversified pipeline of investigational psychedelic-based neuroplastogens designed to address some of the most urgent unmet needs in mental health.

Partnerships

• Even among patients who access care, treatment adequacy remains suboptimal, and around 50% of SAD patients do not achieve adequate response to first line therapies and often deal with chronic medication side effects.
• Atai Therapeutics, Inc. has a strategic investment in Amandala Neuro Limited to accelerate the clinical development of short-duration psychedelics.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:02 UTC. This page is informational and not investment advice.